SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Telik, Inc. Announces Preliminary Agreement on Design of Phase 3 Registration Trial of Telintra® in Low to Intermediate-1 Risk Myelodysplastic Syndrome